Rebecca L. Porter

ORCID: 0000-0002-4848-1275 · 1 paper in corpus

article 2021

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).

·doi:10.1200/jco.2021.39.15_suppl.tps5609

TPS5609 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for recurrent disease. Deeper insight into the roles of disordered tumor vasculature and HIF1α- and VEGF…